RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT00843531
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RAD001 — DRUG
    5 mg/day PO (oral)
  • erlotinib — DRUG
    100 mg/day (oral)

Study Details

The purpose of this study is to test how safe and effective the combination of RAD001 and erlotinib is in patients with neuroendocrine tumors.

Key Dates

First listed
Feb 13, 2009
Start date
Jun 25, 2009
Status verified
Sep 2020
Primary completion
Jul 16, 2013
Completion
Aug 20, 2016

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: RAD001 and erlotinib
    Each 28 day cycle: RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Up to 2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94115-

Find similar trials in San Francisco, CA

By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
University of California, San Francisco· San Francisco, CA

Related Studies